Additional examples of mRNA vaccines include the BNT112 and BNT113 (i.e., individualized vaccines) that are tailored to the specific mutations presented in an individual patient’s tumor and encode five prostate cancer-specific antigens (PAP, PSA, and three undisclosed antigens) and HPV16-derived tumor antigens (HPV16 E6 and E7 oncoproteins), respectively. Here, PROS1 is linked to neoplasm.